NuVasive(R) Announces First Patients in Japan Treated With the XLIF(R) Surgical Technique

NuVasive(R) Announces First Patients in Japan Treated With the XLIF(R) Surgical 
SAN DIEGO, CA -- (Marketwire) -- 02/26/13 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, is proud
to announce that the very first eXtreme Lateral Interbody Fusion
(XLIF(R)) procedures were performed yesterday and today at two
different hospitals in Japan. 
NuVasive has received regulatory Shonin approval for several products
to offer the XLIF surgical technique as a minimally invasive option
for lumbar spine fusion to patients and surgeons in Japan. The
approval furthers the Company's ability to participate in the
Japanese market, adding the XLIF approach to the cervical and
posterior products that were approved for use late last year.  
Russell Powers, NuVasive Executive Vice President of International,
said, "We are absolutely thrilled that NuVasive now offers our
comprehensive portfolio of innovative, procedurally integrated
solutions for spine surgery in Japan, including XLIF. The XLIF
procedure changed spine surgery in the U.S. with a minimally invasive
approach designed to achieve reproducible, superior patient outcomes.
We are eager to introduce XLIF across Japan, and to drive the shift
toward minimally invasive approaches in the world's second largest
spine market. Our initial reception in Japan has been fantastic, and
I applaud all of the NuVasive teams who worked to establish our
Absolutely Responsive direct operation in this exciting new market." 
About XLIF 
XLIF is a minimally invasive surgical (MIS) procedure performed
through the side of the body utilizing proprietary neuromonitoring
and an integrated portfolio of instruments and specialized implants
for treating a range of spinal pathologies. 
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $8.2
billion global spine market. NuVasive's principal product offering is
based on its Maximum Access Surgery, or MAS(R) platform. The MAS
platform combines several categories of solutions that collectively
minimize soft tissue disruption during 
spine surgery with maximum
visualization and safe, easy reproducibility for the surgeon: a
proprietary software-driven nerve avoidance system and
intra-operative monitoring support; MaXcess(R), a unique split-blade
retractor system; a wide variety of specialized implants; and several
biologic fusion enhancers. MAS significantly reduces surgery time and
returns patients to activities of daily living much faster than
conventional approaches. Having redefined spine surgery with the MAS
platform's lateral approach, known as eXtreme Lateral Interbody
Fusion, or XLIF(R), NuVasive has built an entire spine franchise.
With over 80 products today spanning lumbar, thoracic and cervical
applications, the Company will continue to expand and evolve its
offering predicated on its R&D focus and dedication to outstanding
service levels supported by a culture of Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that NuVasive's revenue or earnings projections may turn out to
be inaccurate because of the preliminary nature of the forecasts and
the risk of further adjustment, or unanticipated difficulty in
selling products or generating expected profitability; the uncertain
process of seeking regulatory approval or clearance for NuVasive's
products or devices, including risks that such process could be
significantly delayed; the possibility that the FDA may require
significant changes to NuVasive's products or clinical studies; the
risk that products may not perform as intended and may therefore not
achieve commercial success; the risk that competitors may develop
superior products or may have a greater market position enabling more
successful commercialization; the risk that additional clinical data
may call into question the benefits of NuVasive's products to
patients, hospitals and surgeons; and other risks and uncertainties
more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission. NuVasive's
public filings with the Securities and Exchange Commission are
available at NuVasive assumes no obligation to update
any forward-looking statement to reflect events or circumstances
arising after the date on which it was made. 
Michael J. Lambert 
EVP & Chief Financial Officer
NuVasive, Inc.
Stephan Ogilvie
VP, Corporate Development & Investor Relations
NuVasive, Inc.
Nicholas S. Laudico
The Ruth Group
Press spacebar to pause and continue. Press esc to stop.